DURAClone RE AML

The DURAClone RE AML 1 and RE AML 2 panels enable sensitive detection of rare abnormal cell populations in blood or bone marrow using carefully optimized and titrated antibody combinations. Myeloid progenitor cells expose typical antigen expression characteristics as defined by HLA-DR, CD33, CD34, CD45, and CD117 which might significantly deviate in abnormal progenitor cells together with abnormal expression of further antigens.

  • 2 Combinations each with 8 markers for sensitive detection of residual abnormal immature myeloid cells (MRD) in AML-related clinical research studies, including a shared set of 5 markers with HLA-DR, CD33, CD34, CD45 and CD117
  • Open PE and APC channels for self-verified drop-in markers
  • Pre-formulated antibody panel in a dry unitized assay eliminating antibody cocktailing
  • 25 tests per kit including 2 compensation kits with lot-matched tandem dyes

For Research Use Only. Not for use in diagnostic procedures.

Features

Expert Panels

  • Proven marker combination to detect small populations of normal and abnormal mature B cells
  • Open channels to add drop-in markers to modify for different research questions
  • Designed for assay precision and lot-to-lot consistency

Efficiency

  • Eliminate time spent in titrating different antibody lots
  • Avoid waste that comes from preparing cocktail master mix
  • Simplify inventory management

Consistency

Easy to Use

Explore DURAClone RE AML Models

技术文件

Didn't find what you are looking for? For more results click 此处。